• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Rh Alloimmunization Common Among Transfused Sickle Cell Patients

September 6, 2013

A retrospective study published in the journal Blood suggests that red cell alloimmunization is common among chronically transfused patients with sickle cell disease (SCD), despite the use of Rh-matched blood from minority donors. Researchers identified 146 antibodies among 182 SCD patients receiving blood matched for D, C, E, and K from African American donors. 91 who had unexplained Rh antibodies. Among patients receiving chronic transfusion therapy, 58% were alloimmunized and 45% were Rh immunized. One-third of the Rh antibodies were associated with delayed transfusion reactions. Further high-resolution RH genotyping showed that 87% of individuals experiencing Rh alloimmunization had variant alleles, suggesting that altered RH alleles led to the high prevalence of Rh alloimmunization among these patients.

Reference

1.  Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122: 1062-71.

Filed Under

  • News

Recommended

  • Nipocalimab for Severe Hemolytic Disease of the Fetus and Newborn

  • Nipocalimab Delays Intrauterine Transfusions for Severe Hemolytic Disease of the Fetus and Newborn

  • Transfusion Important for Treatment of Warm Autoimmune Hemolytic Anemia

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

  • Jehovah’s Witness Governing Body Allows Autologous Transfusions

  • RBC Exchange Transfusion for Patients with Severe Babesiosis

  • Oropouche Virus RNA Detected in Blood Donors in Brazil

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley